中国药师
中國藥師
중국약사
CHINA PHARMACIST
2015年
4期
636-640
,共5页
杨杰%王萍%仲鹏磊%周如君
楊傑%王萍%仲鵬磊%週如君
양걸%왕평%중붕뢰%주여군
喹诺酮类%专项整治%用药频度%耐药性%药品不良反应
喹諾酮類%專項整治%用藥頻度%耐藥性%藥品不良反應
규낙동류%전항정치%용약빈도%내약성%약품불량반응
Quinolones%Special rectification%DDDs%Drug resistance%Adverse drug reaction
目的:分析评价南京某三甲医院抗菌药专项整治前后喹诺酮类抗菌药使用情况和发展趋势,为抗菌药临床应用专项整治活动及管理提供依据。方法:调取该院2010年(整治前)和2011~2013年(整治后)所用喹诺酮类抗菌药的使用记录,采用回顾性方法,对该类药物的销售金额、用药频度( DDDs)、限定日费用( DDC)、细菌耐药情况及药品不良反应进行统计分析。结果:整治后(2011~2013年)喹诺酮类抗菌药销售金额及占抗菌药总销售金额比例较整治前(2010年)有明显下降;整治前注射用门冬氨酸洛美沙星的销售金额和DDDs最高,整治后的2012~2013年,莫西沙星注射剂和盐酸左氧氟沙星注射液的销售金额最高,分别位于第1、2位;盐酸左氧氟沙星片和盐酸左氧氟沙星注射液的DDDs最高,分别位于第1、2位;莫西沙星注射剂DDC最高。主要耐药菌葡萄球菌、肠杆菌科细菌、非发酵菌对左氧氟沙星、诺氟沙星、环丙沙星的耐药率有所下降;整治后该院抗菌药所致不良反应例数及喹诺酮类抗菌药所致不良反应占抗菌药不良反应的比例低于整治前。结论:该院通过抗菌药专项整治,喹诺酮类抗菌药的各项应用指标明显改善,喹诺酮类抗菌药的合理应用也取得成效,专项整治的效果比较明显。但该院还应加强对第4代喹诺酮类抗菌药的临床应用加以督导。
目的:分析評價南京某三甲醫院抗菌藥專項整治前後喹諾酮類抗菌藥使用情況和髮展趨勢,為抗菌藥臨床應用專項整治活動及管理提供依據。方法:調取該院2010年(整治前)和2011~2013年(整治後)所用喹諾酮類抗菌藥的使用記錄,採用迴顧性方法,對該類藥物的銷售金額、用藥頻度( DDDs)、限定日費用( DDC)、細菌耐藥情況及藥品不良反應進行統計分析。結果:整治後(2011~2013年)喹諾酮類抗菌藥銷售金額及佔抗菌藥總銷售金額比例較整治前(2010年)有明顯下降;整治前註射用門鼕氨痠洛美沙星的銷售金額和DDDs最高,整治後的2012~2013年,莫西沙星註射劑和鹽痠左氧氟沙星註射液的銷售金額最高,分彆位于第1、2位;鹽痠左氧氟沙星片和鹽痠左氧氟沙星註射液的DDDs最高,分彆位于第1、2位;莫西沙星註射劑DDC最高。主要耐藥菌葡萄毬菌、腸桿菌科細菌、非髮酵菌對左氧氟沙星、諾氟沙星、環丙沙星的耐藥率有所下降;整治後該院抗菌藥所緻不良反應例數及喹諾酮類抗菌藥所緻不良反應佔抗菌藥不良反應的比例低于整治前。結論:該院通過抗菌藥專項整治,喹諾酮類抗菌藥的各項應用指標明顯改善,喹諾酮類抗菌藥的閤理應用也取得成效,專項整治的效果比較明顯。但該院還應加彊對第4代喹諾酮類抗菌藥的臨床應用加以督導。
목적:분석평개남경모삼갑의원항균약전항정치전후규낙동류항균약사용정황화발전추세,위항균약림상응용전항정치활동급관리제공의거。방법:조취해원2010년(정치전)화2011~2013년(정치후)소용규낙동류항균약적사용기록,채용회고성방법,대해류약물적소수금액、용약빈도( DDDs)、한정일비용( DDC)、세균내약정황급약품불량반응진행통계분석。결과:정치후(2011~2013년)규낙동류항균약소수금액급점항균약총소수금액비례교정치전(2010년)유명현하강;정치전주사용문동안산락미사성적소수금액화DDDs최고,정치후적2012~2013년,막서사성주사제화염산좌양불사성주사액적소수금액최고,분별위우제1、2위;염산좌양불사성편화염산좌양불사성주사액적DDDs최고,분별위우제1、2위;막서사성주사제DDC최고。주요내약균포도구균、장간균과세균、비발효균대좌양불사성、낙불사성、배병사성적내약솔유소하강;정치후해원항균약소치불량반응례수급규낙동류항균약소치불량반응점항균약불량반응적비례저우정치전。결론:해원통과항균약전항정치,규낙동류항균약적각항응용지표명현개선,규낙동류항균약적합리응용야취득성효,전항정치적효과비교명현。단해원환응가강대제4대규낙동류항균약적림상응용가이독도。
Objective:To analyze and evaluate the usage and tendency of quinolones before and after the special rectification of antibacterial in one grade III level A hospital in üanjing to provide evidence for the special rectification of antibacterial and manage-ment. Methods:The usage records of quinolones in 2010( before the special rectification)and in 2011-2013( after the special rectifi-cation)were collected,and the sales revenue,DDDs,defined daily cost( DDC),drug resistance and adverse drug reactions( ADR) were analyzed retrospectively. Results:Both the amount and ratio of the sales revenue of quinolones were declined dramatically after the rectification(2011-2013). Among all kinds of quinolones,the sales revenue and DDDs of lomefloxacin aspartate injections was the highest before the rectification while moxifloxacin injections and levofloxacine hydrochloride injections ranked the first and the second respectively in sales revenue after the rectification(2012-2013). As for the DDDs,levofloxacin hydrochloride tablets and levofloxacine hydrochloride injections were the highest after the rectification. Besides,moxifloxacin injections had the highest DDC after the rectifica-tion. Moreover,the drug resistance of the main drug-resistant bacteria( namely staphylococcus,enterobacteriaceae and non fermenta-tion bacteria)to levofloxacin,norfloxacin and ciprofloxacin was declined after the rectification. The adverse drug reactions of levofloxa-cin,lomefloxacin,enoxacin and moxifloxacin were declined year by year after the rectification,and the ADR ratio of quinolones in all anti-bacterial agents was also declined. Conclusion:After the special rectification of antibacterials,the hospital exhibits obvious im-provement in all the application indices of antibacterials,reflecting a good result of the special rectification. However,the hospital still needs to strengthen the inspection over the clinical application of the fourth generation of quinolones.